B cell suppressive therapy led to a delayed diagnosis of Lyme disease

I will be discussing a 20-year-old girl with a 3 year history of multiple sclerosis treated with B cell suppressive therapy . She was prescribed two biological disease-modifying antirheumatic drug (DMARD).

This article was written by Sjowall and colleagues in the journal Frontiers in Neurology.

She was initially prescribed tocilizumab, marketed in the US as Actemra.   Tocilizumab is a monoclonal antibody blocks signals from IL-6 receptors them, is a monoclonal antibody against the interleukin-6 receptor. Tocilizumab can lower the ability of your immune system to fight infections.

She was subsequently prescribed rituximab, sold under the brand name Rituxan, another B- cell treatment.

She suffered for 6 months with knee arthritis and a persistent rash. Lyme disease was considered by dismissed at the Lyme disease tests were negative.

She was finally treated 6 months after the fact with doxyc ycline.

1.         Sjowall J, Xirotagaros G, Anderson CD, Sjowall C, Dahle C. Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab. Front Neurol. 2021;12:645298 .

You can hear more about these cases through his blogs, social media, and YouTube. Sign up for our newsletter to keep up with these cases.

How to Connect with Dr. Daniel Cameron:

We, of course, hope you’ll join the conversation, connect with us and other readers, ask questions, and share your insights.

Dr. Cameron is a Lyme disease expert and the author “Inside Lyme: An expert’s guide to the science of Lyme disease.” He has been treating adolescents and adults for more than 30 years.

Please remember that the advice given is general and not intended as specific advice as to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *